Research Progress on New Anti-tumor Immunotherapy Drugs

doi:10.19803/j.1672-8629.2021.08.05

Abstract

Abstract: Tumors are difficult to cure and pose a serious threat to human lives. Current approaches to tumors include surgery, radiotherapy, chemotherapy, drugs targeting and immunotherapy. In recent years, with more research on tumor immunology and progress in such disciplines as immunology and molecular biology, immunological treatment of tumors has proved to be of good clinical value with advantages in clinical practice. Novel anti-tumor drugs for immunological treatment keep emerging and promise a good prospect of development. Based on the immunity treatment of tumor, this article discussed the basic categories and research progress regarding the new anti-tumor immunity treatment medicine. At the same time, the problems of this medicine and the challenges that China faces in this field were summarized to provide reference and help for the research of new anti-tumor immunity medicine, clinical reasonable medication and anti-tumor treatment.

Key words: tumor, immunotherapy, PD1/PD-L1 inhibitor, tumor vaccine, CAR-T, oncolytic virus

CLC Number:

R979.1

BAO Baiyi, TANG Guanguang, WANG Xingwei, TANG Shubing, LI Xin, HAN Feng. Research Progress on New Anti-tumor Immunotherapy Drugs[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 719-724.

References

[1] Coley WB.The treatment of malignant tumors by repeated inocul-ations of erysipelas with a report of ten original cases[J]. Clinical Orthopaedics & Related Research, 1991, 262: 3-11.
[2] Ishida Y, Agata Y, Shibahara K, et al.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. The EMBO Journal, 1992, 11(11): 3887-3895.
[3] Chen FX, Li X, Liu JQ, et al.Tumor immunoediting and immuno-therapy[J]. Medicine and Philosophy(肿瘤免疫编辑与免疫治疗), 2007, 28(04): 59-61
[4] Yang ZY, Du XL, He XJ, et al.Thymosin α1 combined with FOLFOX4 in the treatment of advanced hepatocellular carcinoma in a complete remission case[J].CMCR(中国临床案例成果数据库), 2020, 2(1): E077-E077.
[5] Zuo ZF.Thymosin α1 combined with immune checkpoint suppression in a case of advanced liver cancer[J]. CMCR(中国临床案例成果数据库), 2020, 2(1): E084-E084.
[6] Graziani G, Tentori L, Navarra P.Ipilimumab: a novel immunosti-mulatory monoclonal antibody for the treatment of cancer[J]. Pharmacological Research, 2012, 65(1): 9-22.
[7] Hodi FS, O'Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. New England Journal of Medicine, 2010, 363(8): 711-723.
[8] Lynch TJ, Bondarenko I, Luft A, et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study[J]. Journal of Clinical Oncology, 2012, 30(17): 2046-2054.
[9] Reck M, Ciuleanu TE, Dols MC, et al.OA03. 02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (Chemo) vs. 4 cycles chemo as first-line (1L) treatment for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA[J]. Journal of Thoracic Oncology, 2020, 16(1): S2.
[10] Kahler KC, Hauschild A.Treatment and side effect managementf CTLA-4 antibody therapy in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2011, 9(4): 277-286.
[11] Dillard T, Yedinak CG, Alumkal J, et al.ANTI-CTLA-4 anti-body therapy associated autoimmune hypophysitis: serious im-mune related adverse events across a spectrum of cancer subtypes[J]. Pituitary, 2010, 13: 29-38.
[12] Fadel F, El Karoui K, Knebelmann B.ANTI-CTLA4 antibody-induced lupus nephritis[J]. N Engl J Med, 2009, 361(2): 211-212.
[13] Li B, Vanroey M, Wang C, et al.Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2009, 15(5): 1623.
[14] Kaiser J, Couzin-Frankel J.Cancer immunotherapy sweeps Nobel for medicine[J]. Science, 2018, 362(6410): 13.
[15] Fan Y, Zhao J, Wang Q, et al.Camrelizumab Plus Apatinib in extensive-stage small-cell lung cancer (PASSION): a multicenter, two-stage, phase 2 trial[J]. Journal of Thoracic Oncology, 2020, 16(2): 299-309.
[16] Zhuo C, Chen G, Huang Y, et al.Camrelizumab Plus Carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. The hancet 2021, 9(3): 305-314.
[17] Tang B, Chi Z, Chen YB, et al. Safety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial[J]. Clinicalr Cancer Research, 2020, 26(16): clincancers. 3922. 2019.
[18] Wang FH, Wei XL, Feng J, et al. Efficacy, safety,correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02) [J]. Journal of Clinical Oncology, 2021, 39(7): JCO. 20. 02712.
[19] Shen L, Guo J, Zhang Q, et al.Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study[J]. Journal for Immunotherapy of Cancer, 2020, 8(1): e000437.
[20] Wang J, Yu X, Lu S, et al.Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC)[J]. Journal of Clinical Oncology, 2020, 38(15_suppl): 9554-9554.
[21] Huang X, Yang Y.Driving an improved CAR for cancer immuno-therapy[J]. Journal of Clinical Investigation, 2016, 126(8): 2795-2798.
[22] Fang J, Ding N, Guo X, et al.αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib[J]. Journal for Immunotherapy of Cancer, 2021, 9(2): e001162.
[23] Shi D, Shi Y, Kaseb AO, et al.Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials[J]. Clinical Cancer Research, 2020, 26(15): 3979-3989.
[24] Li Y, Hermanson DL, Moriarity BS, et al.Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity[J]. Cell Stem Cell, 2018, 23(2): 181-192.
[25] Guo C, Manjili MH, Subjeck JR, et al.Therapeutic cancer vaccines: past, present, and future[J]. Advances in Cancer Research, 2013, 119: 421.
[26] Butterfield LH.Cancer vaccines.[J]. BMJ, 2015, 350: h988.
[27] Young MD, Gooch WM 3rd, Zuckerman AJ, et al. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination[J]. J Med Virol, 2001, 64(3): 290-298.
[28] Beran J.Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients[J]. Expert Opin Biol Ther. 2008; 8(2): 235-247.
[29] Charlton HHK, Vidigal J, Carrondo MJT, et al.Synthetic biology for bioengineering virus-like particle vaccines[J]. Biotechnol Bioeng, 2019, 116(4): 919-935.
[30] Ogi C, Aruga A.Clinical evaluation of therapeutic cancer vaccines[J]. Human Vaccines & Immunotherapeutics, 2013, 9(5): 1049-1057.
[31] Grekova SP, Aprahamian M, Daeffler L, et al.Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer[J]. Cancer Biol Ther, 2011, 12(10): 888-895.